Effect of Rituximab Timing on COVID-19-Related Death in Patients With ANCA-Associated Vasculitis
Treatment with rituximab and immunoglobulin levels may increase risk for COVID-19-related death in ANCA-associated vasculitis.
Treatment with rituximab and immunoglobulin levels may increase risk for COVID-19-related death in ANCA-associated vasculitis.
Immigrants may be at a lower risk for mortality after ischemic stroke compared with long-term residents, but the risk for vascular event recurrence was similar in both populations.
Researchers determined whether machine learning could predict stem cell transplant response in severe scleroderma.